SAT0424 OBESITY LINKS TO PSORIATIC ARTHRITIS (PsA) ACTIVITY, HIGHER PREVALENCE OF CARDIOMETABOLIC DISORDERS AND WORSE PATIENT REPORTED OUTCOMES (PROs): DATA FROM THE RUSSIAN PsA REGISTRY (RU-PsART)
Authors: Y. Korsakova, E. Loginova, E. Gubar, E. Vasilenko, A. Vasilenko, N. Kuznetsova, I. Patrikeeva, T. Korotaeva, A. Lila, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2020)

Background: PsA patients (pts) have an increased risk of cardiovascular (CV) and metabolic (Met) disorders due to the combination of inflammation and increased prevalence of traditional CV risk factors. Only limited data are available on Russian PsA pts. Data was collected from 25 rheumatology clinics of the Russian Federation Objectives: to study, in clinical practice, the prevalence of obesity and its association with PsA activity, CV/Met comorbidities and PROs Methods: 614 (M/F=331(54%)/283(46%) PsA pts fulfilling the CASPAR criteria were included from the RU-PsART cohort. Mean age 45.2±0.52 yrs, PsA duration 5.7±0.27 yrs, PsO duration 15.71±0.56 yrs, DAPSA 28.79±0.75. At baseline (BL) PsA activity was evaluated by Tender Joint Count (TJC68), Swollen Joint Count (SJC66), PGA, physician global assessment by Visual Analog Scale (VAS), DAPSA; PROs according to PtGA VAS, PtPain VAS, HAQ, Work Productivity and Activity Index (WPAI) and Body Mass Index (BMI, kg/m 2 ) were calculated. All pts were split into three groups by BMI (kg/m 2 ): normal&lt;25 (I group), overweight 25-30 (II group), obese&gt;30 (III group). M±m, %, Me [Q25; Q75], χ 2 or Fischer’s exact tests were performed Results: At BL the BMI was 27.7±0.23 kg/m 2 with the following BMI categories: normal - 213 pts (34.7%), overweight - 214 pts (34.8%) and obese - 187 (30.5%). Increased BMI was observed in 65.3% of PsA pts. In all groups, comorbidities were found in 297 out of 614 pts (48%): arterial hypertension in 190 (64%), diabetes mellitus in 44 (14.8%), Met syndrome in 36 (12.1%), Coronary Heart Disease in 22 (7.4%). CV and Met disorders were significantly more common in obese pts with BMI&gt;30 compared to overweight pts and to normal BMI pts; female prevailed (Table 1). Table 1. CV/Met comorbidity in three groups, n (%). I group BMI&lt;25 kg/m 2 II group BMI 25-30 kg/m 2 III group BMI&gt;30 kg/m 2 p Arterial hypertension 28(13.2) 55(25.7) 85(46.5) р&lt;0.0001* Diabetes mellitus 0 15(7) 25(14) р&lt;0.0001** Metabolic syndrome 0(0) 6(2.8) 23(12.8) р&lt;0.0001** Coronary heart disease 2(0.9) 6(2.8) 10(5.6) р&lt;0.026*** *III vs I and II groups, ** III vs II, *** III vs I group At BL pts with BMI&gt;30 had higher PsA activity by DAPSA, HAQ, daily activity impairment by WPAI, PtPin compared to I and II groups (table 2). Table 2. PsA activity and PROs based on BMI categories. I group BMI&lt;25 kg/m 2 II group BMI 25-30 kg/m 2 III group BMI&gt;30 kg/m 2 p DAPSA 22.7 [14.7; 35.8] 24.9 [13.5; 38.5] 27 [17.2; 44.4] р&lt;0,05* HAQ 0.9 [0.5; 1.3] 0.9 [0.5; 1.3] 1 [0.8; 1.6] р&lt;0,05* Daily activity impairment 0.3 [0; 0.5] 0.3 [0; 0.5] 0.4 [0; 0.6] р&lt;0,05* PtPain, mm VAS 50 [30; 66.5] 50 [30; 68] 50 [40; 70] р&lt;0,05** *p&lt;0.05 III vs I and II groups, ** p&lt;0.05 III vs II group Conclusion: In clinical practice, BMI increase was found in the majority of PsA pts. Obesity was associated with higher PsA activity, more prevalence of CV/Met disorders and worse PROs. Obesity requires a change of the pts’ lifestyle, nutrition correction and a right choice of therapy Disclosure of Interests: Yulia Korsakova: None declared, Elena Loginova Speakers bureau: Janssen, ELENA GUBAR: None declared, Elizaveta Vasilenko: None declared, Aleksey Vasilenko: None declared, Natalia Kuznetsova: None declared, Irina Patrikeeva: None declared, Tatiana Korotaeva Grant/research support from: Pfizer, Consultant of: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp &amp; Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Speakers bureau: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp &amp; Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Alexander Lila: None declared, Evgeny Nasonov: None declared